These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38113409)

  • 1. Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness.
    Liu R; Zhu G; Tan J; Shen X; Xing M
    J Natl Cancer Inst; 2024 May; 116(5):694-701. PubMed ID: 38113409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 4. A six-genotype genetic prognostic model for papillary thyroid cancer.
    Shen X; Liu R; Xing M
    Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
    Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
    J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.
    Sang Y; Hu G; Xue J; Chen M; Hong S; Liu R
    Endocrine; 2024 Jul; 85(1):304-312. PubMed ID: 38356100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma.
    Hirokawa T; Arimasu Y; Chiba T; Fujiwara M; Kamma H
    Pathol Int; 2020 Apr; 70(4):217-223. PubMed ID: 31943527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations.
    Soeratman AR; Kartini D; Andinata B; Harahap AS; Sudarsono NC
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2043-2049. PubMed ID: 38918666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
    Lee J; Ha EJ; Roh J; Kim HK
    Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
    Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
    [No Abstract]   [Full Text] [Related]  

  • 17. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Expression Profiles of AHNAK2, DCSTAMP, FN1, and TERT Correlate With Mutational Status and Recurrence in Papillary Thyroid Carcinoma.
    Staubitz-Vernazza JI; Müller C; Heymans A; Nedwed AS; Schindeldecker M; Hartmann M; Kloth M; Schad A; Roth W; Musholt TJ; Hartmann N
    Genes Chromosomes Cancer; 2024 Aug; 63(8):e23256. PubMed ID: 39193983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations.
    Yu PC; Tan LC; Zhu XL; Shi X; Chernikov R; Semenov A; Zhang L; Ma B; Wang Y; Zhou XY; Ji QH; Wei WJ; Wang YL
    Endocr Pract; 2021 Jul; 27(7):698-705. PubMed ID: 33515759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.